BIOMAT Database Logo BIOMAT Database Logo

Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. 1992

R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Department of Internal Medicine, Catholic University, Rome, Italy.

Nicotinamide (NCT) has been shown to be effective in preventing the onset of type 1 diabetes mellitus (IDDM) in mice with non-obese diabetic (NOD) and beta cell damage, mediated by the diabetogenic agents including streptozotocin. NCT therapy in man has been shown to have a beneficial effect on the remission phase of IDDM, and its use is safe. In this open pilot trial we therefore studied the effect of oral NCT administration on insulin secretion rate and islet-cell antibody (ICA) titres in IDDM high risk subjects. NCT (25 mg/10 kg bw) was administered in 6/13 high risk patients identified by a family screening programme. Those subjects tested after eight months without treatment showed a decreasing secretion in comparison to onset baseline (56,1 +/- 37.8 versus 35,5 +/- 12.2), whereas the treated subjects showed an increasing insulin secretion after treatment (26 +/- 10 versus 50.2 +/- 26.6), in spite of ICA persistence. Statistical analysis shows an increased insulin secretion in the treated group versus the untreated group (chi 2 = 3.899, P = 0.048). No side-effects were observed. We conclude that NCT may repair beta-cell function in high risk subjects too if damage is not too severe; furthermore, the effect seems not to be mediated by an immune mechanism.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Anti-adrenal medullary antibodies in IDDM subjects and subjects at high risk of developing IDDM.
January 1988, Diabetes care,
R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Nicotinamide and insulin secretion in normal subjects.
July 1993, Diabetologia,
R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Anti-sympathetic ganglia antibodies and postural blood pressure in IDDM subjects of varying duration and patients at high risk of developing IDDM.
January 1989, Diabetes care,
R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Insulin resistance developing in children with IDDM.
January 1982, Diabetes care,
R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM.
December 1992, Diabetes,
R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Assessment of AlbuSure and its usefulness in identifying IDDM subjects at increased risk for developing clinical diabetic nephropathy.
June 1989, Diabetes care,
R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM.
November 1996, Diabetes,
R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Optical identification of subjects at high risk for developing breast cancer.
June 2013, Journal of biomedical optics,
R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Unaltered antioxidant activity of plasma in subjects at increased risk for IDDM.
August 1998, Free radical research,
R Manna, and A Migliore, and L S Martin, and E Ferrara, and E Ponte, and G Marietti, and F Scuderi, and G Cristiano, and G Ghirlanda, and G Gambassi
Insulin regulation of lipolysis in nondiabetic and IDDM subjects.
December 1989, Diabetes,
Copied contents to your clipboard!